Literature DB >> 30696331

Minocycline and the risk of acute psychiatric events in adolescence: A self-controlled case series.

Ruth Brauer1,2, Maria Herrero-Zazo3, David J Barlow3, Fiona Gaughran1,4, David Taylor1,3,4, Louise M Howard1,4.   

Abstract

BACKGROUND: Minocycline has neurological anti-inflammatory properties and has been hypothesised to have antipsychotic effects. AIM: The aim of this study was to investigate, using routinely collected United Kingdom primary health care data, whether adolescent men and women are more or less likely to receive an urgent psychiatric referral during treatment for acne with minocycline compared with periods of non-treatment.
METHOD: A self-controlled case series using United Kingdom Clinical Practice Research Datalink to calculate the incidence rate ratio of urgent psychiatric referrals for individuals, comparing periods during which minocycline was prescribed with unexposed periods, adjusted for age.
RESULTS: We found 167 individuals who were at the time exposed to minocycline for a mean of 99 days and who received an urgent psychiatric referral. There was no difference in psychiatric referral risk during periods of exposure compared with periods of non-exposure: incidence rate ratio first 6 weeks of exposure 1.96, 95% confidence interval 0.82-4.71, p=0.132; incidence rate ratio remaining exposure period=1.97, 95% confidence interval 0.86-4.47, p=0.107.
CONCLUSIONS: We found no evidence in support of a protective effect of minocycline against severe psychiatric symptoms in adolescence.

Entities:  

Keywords:  Schizophrenia; acute psychiatric referral; tetracycline

Mesh:

Substances:

Year:  2019        PMID: 30696331     DOI: 10.1177/0269881118821852

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  1 in total

Review 1.  Development of Novel Therapeutics Targeting the Blood-Brain Barrier: From Barrier to Carrier.

Authors:  Jia Li; Meng Zheng; Olga Shimoni; William A Banks; Ashley I Bush; Jennifer R Gamble; Bingyang Shi
Journal:  Adv Sci (Weinh)       Date:  2021-06-03       Impact factor: 16.806

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.